Regentis Biomaterials reports first-half 2026 financial results

Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026Expands European commercialization readiness, including surgeon training and regulatory approval of new manufacturing process that improves production yield 400%Strengthene…